TY - JOUR T1 - Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users JF - J Hepatol Y1 - 2011 A1 - Grebely, J. A1 - Matthews, G.V. A1 - Hellard, M. A1 - Shaw, D. A1 - I van Beek A1 - Petoumenos, K. A1 - Alavi, M. A1 - Yeung, B. A1 - Haber, P.S. A1 - Lloyd, A.R. A1 - Kaldor, J.M. A1 - Dore, G.J. A1 - ATAHC study group KW - adherence KW - administration & dosage KW - Adult KW - Antiviral Agents KW - Australia KW - clinical trial KW - Cohort Studies KW - complications KW - drug therapy KW - Drug Users KW - education KW - epidemiology KW - Female KW - HCV KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hiv KW - Humans KW - Infection KW - interferon KW - Interferon Alfa-2a KW - Interferon-alpha KW - Logistic Models KW - Male KW - methods KW - Middle Aged KW - Multicenter Studies KW - New South Wales KW - Patient Compliance KW - Patients KW - peginterferon KW - pegylated KW - pegylated interferon KW - Polyethylene Glycols KW - Prospective Studies KW - Proteins KW - Recombinant Proteins KW - Research KW - Research Support KW - Ribavirin KW - Substance Abuse,Intravenous KW - SVR KW - therapeutic use KW - therapy KW - transmission KW - treatment KW - Treatment Outcome KW - Universities KW - virology KW - Wales KW - Young Adult VL - 55 SP - 76-85 IS - 1 N1 -

PMC3117933

ER -